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Purpose. To evaluate the in vitro and in vivo pancreatic anticancer activity of a nano-sized formulation 
based on novel polyallylamine grafted with 5% mole cholesteryl pendant groups (CH5-PAA).  
Method. Insoluble novel anticancer drug, Bisnaphthalimidopropyldiaaminooctane (BNIPDaoct) was 
loaded into CH5-PAA polymeric self-assemblies by probe sonication.  Hydrodynamic diameters and 
polydispersity index measurements were determined by photon correlation spectroscopy. The in vitro 
cytotoxicity evaluation of the formulation was carried out by the sulforhodamine B dye assay with human 
pancreatic adenocarcinoma BxPC-3 cells while the in vivo study, Xenograff mice were used. In vitro 
apoptotic death cell from the drug formulation was confirmed by flow cytometric analysis. 
Results. The aqueous polymer-drug formulation had a mean hydrodynamic size of 183nm. The drug 
aqueous solubility was increased from negligible concentration to 0.3mgmL
-1
. CH5-PAA polymer alone 
did not exhibit cytotoxicity but the new polymer-drug formulation showed potent in vitro and in vivo 
anticancer activity. The mode of cell death in the in vitro study was confirmed to be apoptotic.The in vivo 
results revealed that the CH5-PAA alone did not have any anti-proliferative effect but the CH5-PAA-drug 
formulation exhibited similar tumour reduction efficacy as the commercial drug, gemcitabine.  
Conclusions. The proposed formulation shows potential as pancreatic cancer therapeutics. 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Ductal adenocarcinoma of the pancreas is the fourth causative death from malignant disease in the Western 
Countries (1). Because of its aggressiveness it usually leads to death sentence. Pancreatic resection 
currently remains the only chance to cure patients, with a 5-year overall survival rate between 7–34 % 
compared to a median survival of 3-11 months for unresected cancer patients. (2-4). Despite the 
application of new combination of chemotherapy and radiation therapy, prognosis remains very poor (5). 
Gemcitabine is currently the drug of choice for treatment with the response rate of 23.8% in pancreatic 
cancer patients (6). However, the relatively low response of gemcitabine means that there is still an urgent 
need for new and more efficient therapies. One group of compounds which has shown promise as 
potential anticancer agents, are the Bisnaphthalimidopropyl (BNIP) diaminoalkylamines. In our 
laboratory BNIP derivatives, Bisnaphthalimidopropyldiaminooctane (BNIPDaoct) had been designed and 
synthesised to exhibit good in vitro cytotoxicity against colon, breast and leukaemia cells (Fig 1).  
Although cell death in those cell lines was confirmed to be apoptotic, the precise mode of action of those 
compounds is yet to be determined although DNA damage is implicated (7-10). The lack of aqueous 
solubility associated with this group of compound has made in vitro and in vivo testing extremely difficult 
(11). Many approaches have been attempted to address this issue. Chemical modifications of the 
bisnaphthalimides both at the naphthalimido rings and the linker alkyl chains had been attempted but with 
limited success (11, 12). 
 
Figure 1 
 
 
                             
Figure 2 
Since BNIPDaoct showed negligible aqueous solubility, harsh solvents such as DMSO have to be 
used to get the drug into solution (7). Recently Thompson and colleagues reported the fabrication of novel 
comb shaped polymers based on the hydrophobic and hydrophilic modification of a water soluble 
polymer backbone, poly(allylamine) (PAA) (13). The polymer forms nano self-assemblies upon the 
aggregation of the hydrophobic pendant groups in aqueous media and has shown to encapsulate 
hydrophobic probes (13). To date, the use of self-assembling polymers for the delivery of hydrophobic 
anticancer agents has been extensively studied (14). These nano-containers have shown to encapsulate 
poorly soluble anticancer drugs such as paclitaxel, etoposide within their lipophilic core via hydrophobic 
interactions (15-17). During their in vivo journey the nano carriers protect the drugs from enzymatic 
degradation resulting in an effective delivery to the target site (18). The advantages of using nano-carriers 
in chemotherapy include increased drug solubility, prolonged drug exposure time, tumour selective drug 
delivery via enhanced permeability and retention effect, improved therapeutic efficacy, decreased side 
effects, and lower drug resistance (19, 20, 21). However, most of the self-assembling polymers consist of 
block copolymers which are formed mainly via copolymerisation of hydrophobic and hydrophilic 
monomers (18,19,21). In this report, we used a novel self-assembling polymer based on modification of 
15kDa water soluble polymer, polyallylamine (PAA) with cholesteryl moieties. There are limited studies 
of this type of polymer construct in drug delivery. To date, only a few reports using hydrophobically 
modified polyethylenimine (20), glycol chitosan (22) have shown promising potential in hydrophobic 
drug delivery. The cross-linked polyallylamine (PAA) has been used clinically as an oral phosphate 
binder (23), however hydrophobically modified PAA as a delivery system for hydrophobic drugs has not 
been reported before. Furthermore the use of modified PAA for biomedical application include 
attachment of hydrophilic moiety (methyl glycolate) (24) or histidine to PAA for gene delivery (25), and 
the use of thiolated PAA as an intestinal permeation enhancer (26). None of the work thus far has 
attempted to attach a cholesteryl pendant group to PAA for hydrophobic drug delivery.  Therefore, the 
novelty of this work lies on the in vitro and in vivo characterisation of a novel biomaterial for the delivery 
of an insoluble novel therapeutic agent. In this study, a formulation using the cationic PAA grafted with 
cholesteryl groups in 5% molar ratio (CH5-PAA, Fig. 2) was applied to enhance the aqueous solubility of 
BNIPDaoct. The CH5-PAA formulation incorporating BNIPDaoct was characterised and the anticancer 
properties of such formulation was studied in both in vitro and in vivo using pancreatic BxPC3 cancerous 
cells. The mechanism by which in vitro cell death occurs was explored using standard molecular 
approaches. 
 
MATERIALS AND METHODS 
 
Materials  
Poly(allylamine) hydrochloride, cholesterol chloroformate, triethylamine, octane sulfonic acid, 
anhydrous sodium acetate, gemcitabine, carbonyl cyanide m-chlorophenylhydrazone and nonenzymatic 
cell-dissociation solution were from Sigma-Aldrich chemical company (UK). Thiopental was bought 
from Sigma, St. Louis, MO. Visking tubing membranes were from Medicell International Ltd. 
(London,UK). GDX PVDF filters were purchased from Whatman, UK. DMSO, methanol and diethyl 
ether were from Fisher Scientific (UK). RPMI 1640 media, 10% heat inactivated fetal bovine serum, 1% 
glutamine, L-gluthamine, penicillin, streptomycin and amphotericine B were from BioWhitaker 
(Belgium). TCA (trichloroacetic acid) and 2% saponin were purchased from Fluka (Switzerland). 
Tetramethylrodamine methyl ester was purchased from Molecular probes. FITC-conjugated annexin 
detection kit was from R&D Systems. 
 
Methods 
 
Synthesis and characterisation of 5 % Cholesteryl -PAA  
Synthesis of 5% mole modification of Cholesteryl-PAA (CH5-PAA, Fig. 2) was carried out as 
described by Thompson and colleagues [30]. Briefly 15kDa PAA-HCl (10 g, Sigma-Aldrich) salt was 
dissolved in doubly distilled water. Sodium hydroxide pellets were added slowly until a pH of 13 was 
achieved and the mixture was stirred for 1 h. The polymer was exhaustively dialysed against water using 
7000 Dalton membrane for 24 h with 6 water changes (at 2 h intervals for first 8 h). The solution was 
recovered from the dialysis tubing and freeze-dried on a 48 h cycle. The free amino PAA (2 g) was 
dissolved in 100 mL chloroform:methanol (1:1 v/v). Triethylamine  (2 mL) was added and the mixture 
was stirred for 0.5 h. Cholesteryl chloroformate (0.6678 g) was dissolved in 20 mL chloroform:methanol 
(1:1 v/v), and then added drop wise to the polymer solution over 2 h at 37 °C. The mixture was then left 
stirring for 24 h at 37 °C. 
After 24 h the solvent was removed using a rotary film evaporator, and the residue washed with diethyl 
ether (3 x 100 mL). The dry residue was dissolved in doubly distilled water (50 mL) and the solution was 
exhaustively dialysed (molar weight cut-off = 7 kDa) against 5 L doubly distilled water for 24 h (6 water 
changes were made). The solution was freeze dried for 48 h and the product was recovered as white 
cotton like solid (2.2 g,, 79 % yield). The polymer was characterised by 
1
HNMR (Bruker UltraShield 400 
MHz) and elemental analysis (Strathclyde University, Glasgow, UK). BNIPDaoct was synthesised as 
previously reported (12). 
 
Preparation of CH5-PAA, BNIPDaoct formulation 
CH5-PAA polymer solution (1 mgmL
-1
) was prepared by dissolving the polymer in water followed 
by probe sonication (10 min). BNIPDaoct (1 mgmL
-1
) was added to the Ch5-PAA solution and sonicated 
for a further 10 min to ensure maximum drug solubilisation had occurred. The solution was filtered using 
0.45 µm syringe filters with prefilters to remove any excess undissolved drug.  
 
Characterisation of novel CH5-PAA, BNIPDaoct formulation 
 
Solubilisation of BNIPDaoct 
BNIPDaoct concentration in self-assemblies was analysed using RP Zorbax ODS 250 mm x 46 
mm x 5 µm HPLC column (Hichrom, UK). The mobile phase consisted of 55:45 (v/v) buffer:acetonitrile 
and the flow rate was 1 mLmin
-1
. The buffer for the mobile phase was made up of 0.432 g octane sulfonic 
acid and 1.64 g anhydrous sodium acetate made up to 200 mL with deionised water, which the solution 
was subsequently pH adjusted to pH 4.5. The column eluent was monitored at 234 nm excitation and 394 
nm emission, using a fluorescent detector (Shimadzu prominence UFLC, UK). The samples were diluted 
with the mobile phase and 20 µL was injected onto the column, the resultant peak at 10 min was 
analysed. A calibration was carried out by dissolving BNIPDaoct in DMSO:water (50:50 v/v) (39 - 625 
µgmL
-1
), R
2
 = 0.999. 
 
Sizing of Nano-aggregates 
Hydrodynamic diameters and polydispersity index measurements were carried out on the CH5-
PAA alone and polymer, drug formulation using a photon correlation spectroscopy (PCS) (Zetasizer 
Nano-ZS, Malvern Instruments, UK). All measurements were conducted in triplicate at 25 °C and an 
average value was determined.  
 
Cell culture 
Human pancreatic adenocarcinoma cell line BxPC-3 (ATCC) was maintained at 37 °C in a humid 
atmosphere with 5% CO2. The cells were grown in RPMI 1640 supplemented with 10% heat inactivated 
fetal bovine serum, 1% glutamine, 2 mM L-gluthamine, 100 Uml
-1
 penicillin, 100 μgmL-1 streptomycin 
and amphotericine B.  
 
Cytotoxic Activity 
Cell viability was evaluated using the sulforhodamine B dye assay (SRB; Sigma-Aldrich) [42]. 
Cells were seeded on 96-well plates at a density of 2 x 10
4
 cells/well and incubated for 24 h at 37 °C in 
5% CO2 atmosphere prior to the addition of different drugs and formulation. Cells were then treated with 
CH5-PAA alone (0-30 g/mL), CH5-PAA-BNIDaoct aqueous formulation (30 g/mL polymer and 0.04-
10 M drug), neat BNIPDaoct was dissolved in DMSO and gemcitabine in PBS, pH 7.4. After 48 h the 
cells were fixed in situ by the addition of 50 μL of cold 50% (w/v) TCA [final concentration, 10% TCA] 
and incubated for 1 h at 4 °C. Supernatants were discarded, and the plates were washed five times with 
water and air-dried. SRB solution (100 μL) at 0.4% (w/v) in 1% acetic acid was added to each well, and 
plates incubated for 10 mins at room temperature. After staining, unbound dye was removed by five 
washes with 1% acetic acid and then the plates were air dried. Bound SRB was subsequently solubilised 
with 200 μL of 10 mM Tris-base solution (pH 10.5) by agitating the plate on a shaker until the colour 
became homogeneous. SRB bound to the cellular protein content was determined by colorimetric 
measurement on an automated plate reader (515 nm). The IC50 values, defined as the drug concentration 
that inhibits 50% of growth compared to untreated cells, were then determined for each drug, polymer 
and formulation using the dose-dependent curves. 
 
Detection of Apoptosis 
 
Flow cytometric analysis of external phosphatidylserine exposure.  
Cells were seeded in 24-well plates at a density of 1 x 10
5
 cells/well and allowed to adhere for 24 
h followed by incubation with CH5-PAA, CH5-PAA-BNIDaoct formulation, BNIPDaoct or gemcitabine 
(1 or 10 μM) for 24 h. Cells were collected and labelled with FITC-conjugated annexin V for 15 min, at 
room temperature, in a Ca
2+
 enriched binding buffer (apoptosis detection kit, R&D Systems). PI 
(propidium iodide) (0.5 μgmL-1) was added to exclude the necrotic cells with disrupted plasma membrane 
permeability, and the cells were analyzed by flow cytometry. Staurosporine-exposed cells (1M) were 
used as a positive control. All data were analyzed using CellQuest software (BD Biosciences, USA). 
 
Measurement of mitochondrial membrane potential.  
Tetramethylrhodamine methyl ester (TMRE) is a cationic lipophilic dye that readily accumulates 
in active mitochondria. For the determination of mitochondrial membrane potential (ΔΨ), the cells were 
seeded in 24-well plates at a density of 1 x 10
5
 cells/well and allowed to adhere for 24 h followed by 
incubation with CH5-PAA, CH5-PAA-BNIDaoct formulation, BNIPDaoct or gemcitabine (1 or 10 μM)  
for 24 h. Drug-treated or non-treated cells were washed in PBS and incubated with 200 nM of TMRE for 
30 min at 37 °C and 5% CO2 and analyzed by flow cytometry on the FL2-H channel. PI (4 μgmL
-1
) was 
used before the last acquisition to exclude dead cells and recorded on FL3-H channel. As a positive 
control, cells already labelled with TMRE for 30 min were treated during 20 min at 37 °C with 200 μM 
final concentration of carbonyl cyanide m-chlorophenylhydrazone (CCCP) which depolarizes 
mitochondria by abolishing the proton gradient across the inner mitochondrial membrane (27). 
 Flow cytometric analysis of DNA fragmentation.  
The DNA content of 1 x 10
5
 cells/well incubated with 1 or 10 μM of CH5-PAA, CH5-PAA- 
BNIDaoct formulation , BNIPDaoct or gemcitabine during 24 h was determined by flow cytometry using 
PI (0.5 μgmL-1), after the cells were permeabilized with 50 μL of 2% saponin solution in PBS (28). After 
permeabilization drug-treated or non-treated cells were washed in PBS and then analyzed by flow 
cytometry on the FL3-H channel.  
 
In Vivo Effect of CH5-PAA-BNIPDaoct formulation on Xenograff mice (Mice implanted 
subcutaneously with BxPC3 tumor cells) 
Female NMRI Nu/Nu mice 6 weeks of age (le Genest-St.-Isle, France) were kept in pathogen-free 
conditions (weight of mice was 24-30 g). All surgical procedures and animal care were carried out 
according to accreditation number 04333 given by the French ministry of agriculture. Human pancreatic 
cancer cell line BxPC-3 was cultured to 90% confluence in RPMI 1640 supplemented with 10 % heat 
inactivated fetal bovine serum, 2 mM L-glutamine, 100 UmL
-1
 penicillin, 100 μgmL-1 streptomycin and 
amphotericine B. The cells were washed twice with cold PBS and harvested with nonenzymatic cell-
dissociation solution for 10 min at 37 °C. The cells were washed 3 times with PBS and kept on ice until 
injection. Mice were transiently anesthetized (<30 s) with a low dose (2.5 mg) of thiopental to place them 
in the restraining tube. The tumour cell suspension (1.8x10
6
 cells in 100 µL of PBS) was injected 
subcutaneously (s.c.) in the right flank of each mouse. When the tumour became palpable (2 weeks), 
measurements in 2 dimensions with vernier calipers were carried out once a week and volume tumours 
calculated according to the formula: (/6) x (a x b2), where a is the largest and b the smallest diameter of 
the tumour. 
Drug treatments were performed twice per week during 4 weeks. Four groups of mice were 
studied: Group 1: Mice (n=13) received intraperitoneal injections (i.p.) of 1mgkg
-1
 CH5-PAA, 0.3 mgkg
-1 
BNIPDaoct aqueous formulation in a volume of 100 µL. Group 2: Mice (n=6) received i.p. injections of 
1mgkg
-1
 CH5-PAA aqueous solution in a volume of 100 µL. Group 3: A group of mice (n=11) received 
i.p. injections of 2.5 mgkg
-1
 of gemcitabine dissolved in PBS. 
 
The treatment efficacy was evaluated by the change in tumour volume during the treatment period. The 
measurement for the tumour volume was performed twice per week during 4 weeks. After 5 weeks of 
treatment, the mice were sacrificed.  Difference between the means of unpaired samples were evaluated 
by the Mann Whitney test and the results were considered statistically different when p<0.05. 
 
RESULTS 
 
Synthesis and characterisation of CH5-PAA 
The 
1
HNMR confirmed the synthesis and the elemental analysis showed the cholesteryl grafting value 
(4.7% mole) was in close agreement with the initial molar feed ratios (13). The proton assignments for CH5-PAA  
are:  0.75, 0.9, 1.0,, 1.1 = CH3 (cholesteryl), 1.1-2.1 = CH2 (cholesteryl and PAA), 2.3 = CH2 (cholesteryl), 2.4-3.2 = 
CH2 (PAA), 4.4 = CH-O (cholesteryl), 5.4 = CH (cholesteryl). 
 
Characterisation of novel CH5-PAA-BNIPDaoct formulation 
At 1 mgmL
-1
, CH5-PAA formed a clear colourless solution. The self-assemblies formed had a 
hydrodynamic radius of 167 nm (Table 1), the low polydispersity index indicated that the aggregates 
formed were mostly uniform in size. CH5-PAA possessed a critical aggregation concentration (CAC) at 
0.02 mgmL
-1
, this was the lowest polymer concentration required for spontaneous self-assembly 
formation to occur (13). The CAC value was previously determined with the use of a hydrophobic methyl 
orange probe, whereby a hypsochromic shift was observed on encapsulation into the self-assemblies 
driven by non-covalent hydrophobic interactions (13). 
 
Table 1  
 
The drug solubilisation capacity of the PAA amphiphile was determined using HPLC analysis. 
CH5-PAA was capable of solubilising 0.3 mgmL
-1
 of the BNIPDaoct at 1 mgmL
-1
 polymer concentration 
using 1:1 initial drug:polymer loading weight ratio. The yellowish drug powder clumped together when it 
was mixed with water. Filtered BNIPDaoct aqueous solution showed negligible aqueous solubility while 
in the presence of PAA polymeric self-assemblies, an optically clear and yellowish solution was formed. 
The hydrodynamic radius of the polymeric self-assemblies increased from 167 nm to 183 nm in the 
presence of BNIPDaoct The low PDI indicates uniform size population in the formulation (Table 1). 
 
In vitro Cytotoxic Activity 
The human pancreatic cells (BxPC3) were subjected to CH5-PAA, CH5-PAA-BNIDaoct 
formulation, BNIPDaoct or gemcitabine treatments. The anti-proliferative effects were evaluated with 
final concentrations ranging from 0.04 to 10 μM for 48 h, resulting in a dose-dependent inhibition of cell 
growth, quantified by SRB dye assay (Fig. 3). The polymer (CH5-PAA) alone up to 30 mg/mL had no 
cytoxicity on the pancreatic cancer cells (supplementary data) while CH5-PAA-BNIPDaoct formulation 
and BNIPDaoct had a half maximal inhibitory concentration (IC50) of 1.06  0.13 M and 1.11  0.12 
M, respectively. The presence of polymer did not alter the cytotoxicity effect of BNIPDaoct. BxPC3 
cells exhibited a notably lower sensitivity to gemcitabine with an IC50 value of 8.5  0.18 M indicating 
that gemcitabine is less effective than BNIPDaoct. 
 
 
Figure 3  
 
In Vitro Apoptotic Analysis 
Mediated CH5-PAA-BNIDaoct formulation and BNIPDaoct apoptosis were studied by the 
combination of a number of assays. Flow cytometry experiments were carried out at least 3 times and in 
duplicates (Fig. 4-6). Although drug concentration of 5M was attempted, similar results were obtained 
with 1 and 10 M drug concentrations (data not shown). With the exception of the DNA fragmentation 
assay, the cells analysed were gated for the live population. In general, the best results were obtained with 
compounds at 10 M concentration.  
In apoptotic cells, the membrane phospholipid phosphatidylserine (PS) is translocated from the 
inner to the outer leaflet of the plasma membrane, thereby exposing PS to the external cellular 
environment. Substantial increase in phosphatidylserine exposure induced by CH5-PAA-BNIPDaoct 
formulation (80%) and BNIPDaoct (90%) were observed using Annexin V/PI assays (Fig. 4) at 10 M 
drug concentration when compared with the positive control staurosporine (1 M). It is interesting to note 
that at 10 M drug concentration, both CH5-PAA and gemcitabine showed similar levels of annexin V 
positive cells. No significant effect was detected with 1 M drug concentration.  
                               
Figure 4 
Mitochondrial damage as a result of depolarized Δψm, is often observed during the early apoptotic 
stages, and may be a prerequisite for cytochrome c release (28). Therefore, experiments were carried out 
to determine whether drug-treated tumour cells induced a decrease in Δψm. The results shown in Fig. 5 
demonstrated a significant increase in the percentage of cells exhibiting reduced Δψm upon drug 
treatment during 24h with 1 or 10 M of either CH5-PAA-BNIDaoct formulation or BNIPDaoct. The 
effect obtained was comparable to that observed with the positive control treatment using CCCP and 
higher than that of the standard drug gemcitabine. 
                                    
Figure 5 
The above observations prompted us to investigate the changes occurring in the nuclear material 
of drug-treated cells by flow cytometry analysis after cell permeabilization and the labelling with PI. As 
shown in Figure 6, both CH5-PAA-BNIDaoct formulation and BNIPDaoct at 10 M concentrations and 
after 24h exposure induced DNA fragmentation in BxPC3 cells at a level significantly higher than that 
shown when using Staurosporine as a positive control. Furthermore those effects were five times the 
mean value observed when using 10 M concentration of gemcitabine. Interestingly in this experiment, 
polymer CH5-PAA exhibited negligible DNA fragmentation hence confirming the low toxicity of the 
polymer. 
                               
Figure 6 
 
In Vivo Effect of CH5-PAA-BNIPDaoct formulation on xenograff tumour (BxPC3 cell line implanted) 
To further analyze the anti-proliferative activity of the drug-formulation, the effect of BNIP 
derivative was assessed on mice, which were implanted subcutaneously with BxPC3 tumour cells. Figure 
7 presents a scatter plot of mean tumour volumes after administration of drugs. All formulations were 
well tolerated with no gross toxicity reaction observed. Statistical analysis using the Mann Whitney test 
showed significant difference in tumour size between CH5-PAA-BNIPDaoct formulation and CH5-PAA 
treated mice after 6, 9, 12, 16 days treatment (*p values= 0.028, 0.01, 0.003, 0.028 respectively). This 
indicates that CH5-PAA itself did not exhibit any anti-proliferative activity. After the 3
rd
 injection, 
statistically significant difference in tumour size between CH5-PAA-BNIPDaoct formulation and 
gemcitabine treated mice was observed (p=0.006) (at day 6 after the beginning of IP treatment). Note that 
in this experiment the in vivo data showed the effectiveness of CH5-PAA-BNIPDaoct formulation in 
reducing tumour growth in mice. The CH5-PAA polymer alone was used as a negative control i.e. tumour 
size keeps increasing with time whereas Gemcitabine a known anticancer drug currently used in the clinic 
against pancreatic cancer was used as a positive control.  
                                  
Figure 7 
 
                         
Figure 8  
 
At the end of the in vivo study termination, the mean tumour volume of each group was 
determined. The Mann Whitney test  was then applied to compare the values for each group. The group of 
mice treated with CH5-PAA alone did not experience a reduction in tumour growth while mice treated 
with both BNIPDaoct formulation (p=0.0159) and gemcitabine (p =0.0138) had a statistically significant 
decrease in tumour size compared to CH5-PAA.  This strongly support that CH5-PAA-BNIPDaoct 
formulation is at least as efficient as gemcitabine. Indeed there is no statistical difference between the 
CH5-PAA-BNIPDaoct formulation and gemcitabine.  
 
 
DISCUSSION 
 
Most pancreatic cancers are not diagnosed until after they have metastasized. Standard treatments 
for advanced disease include radiotherapy and/or chemotherapy regimens. However, radiotherapy is often 
toxic and the chemotherapy which includes drugs such as 5-fluorouracil (5-FU) and gemcitabine are 
either ineffective or effective for only short duration. Although gemcitabine has been shown to provide an 
improvement in the life quality (29), high intrinsic resistance of pancreatic cancer to currently available 
agents, might explain the failure of gemcitabine alone and gemcitabine -based combination chemotherapy 
to achieve great success (30, 31, 32). Therefore, new therapeutic strategies are urgently needed. The 
search for means to interfere with the tumour cell proliferation led to the identification of a large number 
of natural and synthetic compounds that could revert the cell morphology of various cancer cells to 
apparently normal phenotype (33). Interestingly some of these molecules exhibited histone deacetylase 
inhibitory activity. For instance, pancreatic adenocarcinoma cell lines IMIM-PC-1, IMIM-PC2 and RWP-
1 have been shown to be highly sensitive to apoptosis-inducing effect of Trichostatin (TSA) and 
suberoylanilide hydroxamid (SAHA) (34). Moreover, it has been reported that TSA could synergize with 
gemcitabine (35) or proteasome inhibitor PS-341 to induce apoptosis of pancreatic tumor cell lines [36]. 
We have recently reported that a number of class I, II and III deacetylase inhibitors, 
bisnaphthalimidopropyl (BNIPDaoct) could induce apoptosis of various human pancreatic cancer cell 
lines in vitro (37, 38).  The above observations provide a rationale to investigate further the anti-
pancreatic tumour properties of BNIPDaoct. The bulky multi-ring structures and long alkyl chains of 
    
BNIPDaoct are essential to preserve the activity of the drug. However, at the same time this has resulted 
in undesirable physico-chemical properties of the drug. Negligible concentration of BNIPDaoct was 
obtained when the drug was dissolved in aqueous solution As a result; in vitro assays were conducted 
using harsh solvents such as DMSO in our previous work (39, 40). The poor aqueous solubility of the 
drug also restricts in vivo investigations since a drug is commonly dissolved in aqueous media for in vivo 
parenteral administration.  
  
Using the nano-carriers formed by amphiphilic polymer CH5-PAA, an aqueous formulation of 
CH5-PAA-BNIPDaoct was successfully prepared with a drug loading efficiency of 30%. Upon 
incorporation of the novel anticancer drug, BNIPDaoct into the polymeric self-assembly a slight increase 
in aggregate size was observed. The size increased from 167 nm (unloaded CH5-PAA) to 183 nm in the 
presence of the drug (Table 1). This increase in hydrodynamic radius can be attributed to expansion of the 
hydrophobic core in order to accommodate the BNIPDoact molecules (41). The polydispersity index was 
slightly lower for the CH5-PAA-BNIPDaoct formulations (0.167) than for the Ch5-PAA (0.190), this 
indicated the drug loaded aggregated were of a more uniform size distribution.  The size of 178nm is ideal 
since it has been reported the size of <183nm is important to ensure long circulation time in vivo (19). 
The reason being at this size, the nanoparticles are able to avoid the uptake of mononuclear phagocytic 
system (MPS) present in the liver and spleen. As a result, prolonged circulation will lead to accumulation 
at the tumour through the enhanced permeation and retention (EPR) effect (19)  
When human pancreatic (BxPC3) cells were exposed to the novel CH5-PAA-BNIPDaoct 
formulation in vitro, they possessed a notably lower IC50 (1.06 μM) than that of commercially available 
gemcitabine (8.50 μM) demonstrating that BxPC3 cells are more sensitive to the cytotoxic effect of the 
polymer-drug formulation (Fig. 3). The study was also carried out with the free drug dissolved in DMSO. 
The difference between the IC50 of the free drug and the CH5-PAA-BNIPDaoct formulation was 
negligible. This indicated that the polymer did not enhance the cytotoxic effect of the drug on the cells 
and this corresponds with the non-cytotoxic profile of CH5-PAA at the concentrations tested (Fig 3). 
However, the formulation is still advantageous for in vivo administration as it is desirable to eliminate the 
use of harsh solvents which can cause toxic side effects to the patient. The non-volatile nature of the 
formulation will result in greater dose reproducibility and ease of administration.  
In vitro analysis of the CH5-PAA-BNIPDaoct formulation and BNIPDaoct alone confirm that both 
caused cell death by apoptosis. This is demonstrated by substantial phosptatidylserine exposure on the 
outer cell membrane, high mitochondrial depolarisation and large increase in DNA fragmentations (Fig 4-
6). Unlike polymer, drug formulation and BNIPDaoct alone, gemcitabine at 10µM did not significantly 
increase the apoptosis and mitochondrial membrane depolarisation in cells compared to the positive 
controls (Fig 4-6). However, gemcitabine showed substantial DNA fragmentations (Fig 6) indicating the 
cytotoxic effect of gemcitabine is different from BNIPDaoct and the formulations. CH5-PAA alone did 
not cause any substantial increase in apoptosis and mitrochondrial membrane depolarisation in cells 
(<20%) and negligible DNA fragmentation was observed (<5%), corresponding with the non-cytotoxic 
effect observed in Fig 3.  
The CH5-BNIPDaoct formulation (1 mgmL
-1
, 0.3 mgmL
-1
) was administered in vivo to nude 
tumour bearing mice over a 4 week period. The study found that the Ch5, BNIPDaoct formulation was 
capable of reducing tumour growth rate when compared to CH5 alone. Although the BNIPDaoct dose 
used in the formulation is 8-fold less than gemcitabine, the reduction in tumour growth was comparable 
to the current commercially available drug gemcitabine for anticancer treatment. The reduction in tumour 
size was significant using the CH5-PAA-BNIPDaoct formulation (p< 0.05) compared to the polymer 
alone CH5-PAA. It has been reported that glycol chitosan modified with sterol structure, cholanic acid 
was able to entrapped docetaxel with the particle size of 320nm and exhibited higher antitumour efficacy 
in lung cancer cells bearing mice than free docetaxel. The authors showed reduced in vivo anticancer drug 
toxicity compared to free docetaxel and attributed this effect due to the ability of nano-size particles to 
preferentially localised in tumour tissues (22). Chytil and colleagues demonstrated that N-(2-
hydroxypropyl)methacrylamide (HPMA)- doxorubicin conjugate modified with cholesteryl pendant 
groups resulted in significant tumour regression with long term survival in mice bearing EL-4 T cell 
lymphoma compared to other alkyl chains substituents such as dodecyl and oleic acid (41). This indicates 
that the presence of cholesterol moieties is beneficial although the exact mechanism is not known. In this 
study, comparison between free drug and the formulation was not possible due to the insolubility of the 
drug in aqueous solution for in vivo administration. Based on other similar work, it is hypothesized that 
EPR effect resulted in the antitumour efficacy observed in this study. 
 
CONCLUSION  
Pancreatic cancer remains an untreatable disease, which in most cases is uniformly lethal. Here we 
show that polyallylamine grafted with cholesteryl moieties (CH5-PAA) was able to increase the water 
solubility of a practically insoluble anticancer agent, BNIPDaoct. The drug loaded self-assembled 
aggregates had a mean diameter of 178nm with a narrow size distribution. This formulation showed a 
greater cytotoxic effect in vitro on human pancreatic carcinoma cells than the leading drug gemcitabine in 
human pancreatic cancer cells, BxPC3 while the polymer itself was non-cytotoxic. Despite the 
BNIPDaoct dose was 8-fold less than gemcitabine, the formulation was able to reduced tumour growth in 
xenograft mice with results comparable to gemcitabine. The results of this study indicate that CH5-PAA-
BNIPDaoct has great potential as a suitable therapeutic alternative to gemcitabine for treatment of 
pancreatic cancer. 
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